JP2019014684A - 真菌感染における宿主応答抑制剤 - Google Patents

真菌感染における宿主応答抑制剤 Download PDF

Info

Publication number
JP2019014684A
JP2019014684A JP2017134071A JP2017134071A JP2019014684A JP 2019014684 A JP2019014684 A JP 2019014684A JP 2017134071 A JP2017134071 A JP 2017134071A JP 2017134071 A JP2017134071 A JP 2017134071A JP 2019014684 A JP2019014684 A JP 2019014684A
Authority
JP
Japan
Prior art keywords
vnut
compound
group
atp
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017134071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019014684A5 (https=
Inventor
健太 丸山
Kenta Maruyama
健太 丸山
芳則 森山
Yoshinori Moriyama
芳則 森山
政壽 野村
Masatoshi Nomura
政壽 野村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Priority to JP2017134071A priority Critical patent/JP2019014684A/ja
Publication of JP2019014684A publication Critical patent/JP2019014684A/ja
Publication of JP2019014684A5 publication Critical patent/JP2019014684A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017134071A 2017-07-07 2017-07-07 真菌感染における宿主応答抑制剤 Pending JP2019014684A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017134071A JP2019014684A (ja) 2017-07-07 2017-07-07 真菌感染における宿主応答抑制剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017134071A JP2019014684A (ja) 2017-07-07 2017-07-07 真菌感染における宿主応答抑制剤

Publications (2)

Publication Number Publication Date
JP2019014684A true JP2019014684A (ja) 2019-01-31
JP2019014684A5 JP2019014684A5 (https=) 2020-08-27

Family

ID=65356397

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017134071A Pending JP2019014684A (ja) 2017-07-07 2017-07-07 真菌感染における宿主応答抑制剤

Country Status (1)

Country Link
JP (1) JP2019014684A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225368A1 (ja) 2023-04-28 2024-10-31 学校法人 久留米大学 アデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤、乾癬治療剤並びにアデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤及び乾癬治療剤の製造のための化合物の使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131073A (ja) * 1999-11-09 2001-05-15 Sumitomo Pharmaceut Co Ltd 疼痛治療剤
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
WO2009116546A1 (ja) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001131073A (ja) * 1999-11-09 2001-05-15 Sumitomo Pharmaceut Co Ltd 疼痛治療剤
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
WO2009116546A1 (ja) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOL. PHARM. BULL., vol. 39, JPN6022010429, 2016, pages 770 - 777, ISSN: 0004729001 *
EUROPEAN JOURNAL OF PAIN, vol. 12, JPN6022010427, 2008, pages 284 - 292, ISSN: 0004729000 *
EXPERIMENTAL NEUROLOGY, vol. 254, JPN6021024946, 2014, pages 41 - 53, ISSN: 0004729003 *
JPN. J. MED. MYCOL., vol. 44, JPN6021024944, 2003, pages 193 - 196, ISSN: 0004728998 *
NEUROCHEMISTRY INTERNATIONAL, vol. 99, JPN6021024949, 2016, pages 85 - 93, ISSN: 0004729005 *
NEUROPHARMACOLOGY, vol. 47, JPN6021024948, 2004, pages 286 - 294, ISSN: 0004729004 *
SCI. TRANSL. MED., vol. Vol. 3, Issue 101, JPN6021024945, 2011, pages 101 - 91, ISSN: 0004728999 *
ソルト・サイエンス研究財団助成研究報告書２ 医学 食品科学編, vol. 2015, JPN6021024943, March 2017 (2017-03-01), pages 221 - 226, ISSN: 0004729002 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024225368A1 (ja) 2023-04-28 2024-10-31 学校法人 久留米大学 アデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤、乾癬治療剤並びにアデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤及び乾癬治療剤の製造のための化合物の使用
EP4696306A1 (en) 2023-04-28 2026-02-18 Kurume University Adenosine triphosphate secretion inhibitor, hepatic stellate cell activation inhibitor, hepatic stellate cell deactivator, hepatic fibrosis therapeutic agent, non-alcoholic steatohepatitis therapeutic agent, psoriasis therapeutic agent, and use of compound for producing adenosine triphosphate secretion inhibitor, hepatic stellate cell activation inhibitor, hepatic stellate cell deactivator, hepatic fibrosis therapeutic agent, non-alcoholic steatohepatitis therapeutic agent, and psoriasis therapeutic agent

Similar Documents

Publication Publication Date Title
US11957931B2 (en) Compositions and methods for treating vitiligo
Zhao et al. 2-Deoxy-d-glucose treatment decreases anti-inflammatory M2 macrophage polarization in mice with tumor and allergic airway inflammation
Hall et al. The AMPK agonist 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation‐associated cachectic muscle wasting
Long et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis
Autmizguine et al. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications
Hu et al. Crosstalk between autophagy and intracellular radiation response
Muscoli et al. Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids
Palin et al. Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats
Zhang et al. Minocycline promotes cardiomyocyte mitochondrial autophagy and cardiomyocyte autophagy to prevent sepsis-induced cardiac dysfunction by Akt/mTOR signaling
KR20200121780A (ko) 높은 농도에서 핵산을 포함하는 제제
Shan et al. Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin
JP2019511495A (ja) ＧＳＫ３β阻害薬チデグルシブによるＣＤＫＬ５障害の治療
Gardner et al. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis
KR20050085966A (ko) 레닌-안지오텐신계 억제제의 용도
EP4237561A1 (en) Treatment of cardiovascular disease
Mertes et al. Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation
Ma et al. Activated FMS‐like tyrosine kinase 3 ameliorates angiotensin II‐induced cardiac remodelling
Gilbertie et al. Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology
Menegola et al. Dysmorphogenic effects of some fungicides derived from the imidazole on rat embryos cultured in vitro
JP2019014684A (ja) 真菌感染における宿主応答抑制剤
Nieto et al. Comparison of conventional and lipid emulsion formulations of amphotericin B: pharmacokinetics and toxicokinetics in dogs
Thorsen et al. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats
Edmonds et al. Hypoxia and the rheumatoid joint: immunological and therapeutic implications
WO2017126700A1 (ja) 小胞型ヌクレオチドトランスポーター活性阻害剤
Kanamoto et al. Beneficial effects of follistatin in hepatic ischemia-reperfusion injuries in rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200706

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220914